Nuclear localization of LDL receptor-related protein 1B in mammary gland carcinogenesis.
Breast cancer
LRP1B
NEAT1
Nuclear localization
Prognosis
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
21
04
2018
accepted:
12
12
2018
revised:
10
11
2018
pubmed:
5
1
2019
medline:
28
5
2020
entrez:
5
1
2019
Statut:
ppublish
Résumé
LRP1B intracellular domain is released and transported to the nucleus; however, pathological consequences of this nuclear transport are largely unclear. We aimed to unravel the pathobiological significance of nuclear localization of LRP1B intracellular domain in mammary gland carcinogenesis. Immunohistochemical staining using antibodies for LRP1B intracellular domain was performed to determine LRP1B expression in 92 invasive ductal breast carcinomas. LRP1B immunoreactivity was detected in the surface membrane and cytoplasm of 60 of 92 invasive ductal carcinomas and in the nucleus of 15 of 92 carcinomas. Nuclear LRP1B was significantly associated with poor patient prognosis, particularly luminal A type breast cancer, where it was significantly related to nodal metastasis. Doxycycline-dependent nuclear expression of LRP1B intracellular domain was established in cultured breast cancer cells. Enforced nuclear expression significantly increased Matrigel invasion activity in MCF-7 and T47D luminal A breast cancer cells. Moreover, enforced nuclear expression of LRP1B intracellular domain facilitated MCF-7 cells growth in mammary fat pad of nude mice, which was supplemented with estrogen. Comprehensive microarray-based analysis demonstrated that nuclear expression of LRP1B intracellular domain significantly increased long non-coding RNA nuclear paraspeckle assembly transcript 1 (NEAT1) expression, which facilitates breast cancer invasion with poor prognosis. Nuclear-localized LRP1B intracellular domain promoted breast cancer progression with poor prognosis, possibly through the NEAT1 pathway. Nuclear transport of LRP1B intracellular domain could be a therapeutic target for breast cancer patients. KEY MESSAGES: Nuclear LRP1B was significantly associated with poor patient prognosis. Nuclear LRP1B increased Matrigel invasion activity of breast cancer cells. Nuclear expression of LRP1B intracellular domain increased NEAT1 expression.
Identifiants
pubmed: 30607440
doi: 10.1007/s00109-018-01732-2
pii: 10.1007/s00109-018-01732-2
doi:
Substances chimiques
LRP1B protein, human
0
Receptors, LDL
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-268Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
EMBO J. 2006 Mar 22;25(6):1242-52
pubmed: 16511561
J Biol Chem. 2001 Aug 3;276(31):28889-96
pubmed: 11384978
J Cell Mol Med. 2018 Feb;22(2):1026-1033
pubmed: 29164763
Cell. 2000 Feb 18;100(4):391-8
pubmed: 10693756
Cancer Sci. 2006 Oct;97(10):1070-4
pubmed: 16918994
J Neurochem. 2000 Apr;74(4):1489-97
pubmed: 10737605
Database (Oxford). 2014 Mar 07;2014:bau015
pubmed: 24608173
Nat Genet. 2011 Dec 25;44(2):133-9
pubmed: 22197931
Exp Cell Res. 2017 Aug 1;357(1):1-8
pubmed: 28408316
J Biol Chem. 2003 Sep 26;278(39):38029-39
pubmed: 12832415
Mol Cancer. 2017 Jun 14;16(1):104
pubmed: 28615056
Cancer Res. 2004 Jun 1;64(11):3741-7
pubmed: 15172977
Atherosclerosis. 2011 Jun;216(2):342-7
pubmed: 21420681
Am J Pathol. 2008 May;172(5):1355-62
pubmed: 18403601
Nature. 2003 Mar 27;422(6930):438-41
pubmed: 12660785
J Biol Chem. 2007 Mar 9;282(10):7504-11
pubmed: 17227771
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nature. 1975 Aug 7;256(5517):495-7
pubmed: 1172191
Cancer Res. 2000 Apr 1;60(7):1961-7
pubmed: 10766186
Nat Rev Cancer. 2009 Sep;9(9):631-43
pubmed: 19701242
J Biol Chem. 2004 Aug 13;279(33):34302-10
pubmed: 15180987
Nat Cell Biol. 1999 Oct;1(6):E157-62
pubmed: 10559979
J Biol Chem. 2002 May 24;277(21):18736-43
pubmed: 11907044
J Neurochem. 2007 Apr;101(2):517-29
pubmed: 17326769
Lab Invest. 2002 May;82(5):639-43
pubmed: 12004004
J Clin Invest. 2017 Sep 1;127(9):3421-3440
pubmed: 28805661
Pathol Oncol Res. 2018 Jan;24(1):109-113
pubmed: 28401449
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Carcinogenesis. 2012 Mar;33(3):548-54
pubmed: 22226915
Yale J Biol Med. 2012 Mar;85(1):19-28
pubmed: 22461740
Appl Immunohistochem Mol Morphol. 2014 Mar;22(3):213-21
pubmed: 24614150
Breast Cancer Res Treat. 2015 Jul;152(1):199-208
pubmed: 26033707
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4
pubmed: 388439
Oncotarget. 2016 Oct 18;7(42):68721-68733
pubmed: 27626682
Urol Oncol. 2016 Nov;34(11):522
pubmed: 27814882
Am J Physiol Cell Physiol. 2008 Aug;295(2):C529-37
pubmed: 18495814